NCT00867685View on ClinicalTrials.gov

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2009

Study Completion Date

April 30, 2009

Conditions
Healthy
Interventions
DRUG

AZD2624

Single dose of 40 mg AZD2624 liquid suspension, PO

DRUG

AZD2624

Single dose of 40 mg AZD 2624 (2x20mg tablets), PO

Trial Locations (1)

Unknown

Research Site, Philadelphia

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY